Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

Jonathan G Pol^{1

2

3

4

5}, Sarah Lévesque^{1

2

3

4

5}, Samuel T Workenhe^{6

7

8}, Shashi Gujar^{9

10

11

12}, Fabrice Le Boeuf^{13

14}, Derek R Clements⁹, Jean-Eudes Fahrner^{1

15

16}, Laetitia Fend¹⁶, John C Bell^{13

14}, Karen L Mossman^{6

7

8}, Jitka Fucikova^{17

18}, Radek Spisek^{17

18}, Laurence Zitvogel^{1

15}, Guido Kroemer^{1

2

3

4

5

19

20

21}, Lorenzo Galluzzi^{4

22

23}

Affiliations

¹ Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
² INSERM, Paris, France.
³ Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.
⁴ Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France.
⁵ Université Pierre et Marie Curie/Paris VI, Paris, France.
⁶ McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.
⁷ Institute for Infectious Disease Research, McMaster University, Hamilton, ON, Canada.
⁸ Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
⁹ Department of Pathology, Dalhousie University, Halifax, NS, Canada.
¹⁰ Department of Microbiology and Immunology, Dalhousie University, NS, Canada.
¹¹ Department of Biology, Dalhousie University, NS, Canada.
¹² Centre for Innovative and Collaborative Health Sciences Research, Quality and System Performance, IWK Health Centre, Halifax, NS, Canada.
¹³ Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
¹⁴ Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
¹⁵ INSERM, Villejuif, France.
¹⁶ Transgene S.A., Illkirch-Graffenstaden, France.
¹⁷ Sotio a.c., Prague, Czech Republic.
¹⁸ Department of Immunology, 2nd Faculty of Medicine, University Hospital Motol, Charles University, Prague, Czech Republic.
¹⁹ Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.
²⁰ Pôle de Biologie, Hôpital Européen Georges Pompidou, Paris, France.
²¹ Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.
²² Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
²³ Sandra and Edward Meyer Cancer Center, New York, NY, USA.

PMID: 30524901
PMCID: PMC6279343
DOI: 10.1080/2162402X.2018.1503032

Review

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

Jonathan G Pol et al. Oncoimmunology. 2018.

. 2018 Aug 27;7(12):e1503032.

doi: 10.1080/2162402X.2018.1503032. eCollection 2018.

Authors

Affiliations

¹ Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
² INSERM, Paris, France.
³ Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.
⁴ Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France.
⁵ Université Pierre et Marie Curie/Paris VI, Paris, France.
⁶ McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.
⁷ Institute for Infectious Disease Research, McMaster University, Hamilton, ON, Canada.
⁸ Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
⁹ Department of Pathology, Dalhousie University, Halifax, NS, Canada.
¹⁰ Department of Microbiology and Immunology, Dalhousie University, NS, Canada.
¹¹ Department of Biology, Dalhousie University, NS, Canada.
¹² Centre for Innovative and Collaborative Health Sciences Research, Quality and System Performance, IWK Health Centre, Halifax, NS, Canada.
¹³ Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
¹⁴ Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
¹⁵ INSERM, Villejuif, France.
¹⁶ Transgene S.A., Illkirch-Graffenstaden, France.
¹⁷ Sotio a.c., Prague, Czech Republic.
¹⁸ Department of Immunology, 2nd Faculty of Medicine, University Hospital Motol, Charles University, Prague, Czech Republic.
¹⁹ Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.
²⁰ Pôle de Biologie, Hôpital Européen Georges Pompidou, Paris, France.
²¹ Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.
²² Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
²³ Sandra and Edward Meyer Cancer Center, New York, NY, USA.

PMID: 30524901
PMCID: PMC6279343
DOI: 10.1080/2162402X.2018.1503032

Abstract

Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.

Keywords: CAVATAK; DNX-2401; HF10; MV-NIS; Maraba MG1; Pexa-Vec; REOLYSIN; T-VEC.

PubMed Disclaimer

References

1. Yue C, Jiang Y, Li P, Wang Y, Xue J, Li N, Li D, Wang R, Dang Y, Hu Z, et al. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy. Oncoimmunology. 2018;7:e1438111. doi: 10.1080/2162402X.2018.1438111. - DOI - PMC - PubMed
1. Wu X, Giobbie-Hurder A, Connolly EM, Li J, Liao X, Severgnini M, Zhou J, Rodig S, Hodi FS Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma. Oncoimmunology. 2018;7:e1440930. doi: 10.1080/2162402X.2018.1440930. - DOI - PMC - PubMed
1. Johnson CB, Win SY.. Combination therapy with PD-1/PD-L1 blockade: an overview of ongoing clinical trials. Oncoimmunology. 2017;7. doi: 10.1080/2162402X.2017.1408744. - DOI - PMC - PubMed
1. Kaderbhai CG, Richard C, Fumet JD, Aarnink A, Ortiz-Cuaran S, Perol M, Foucher P, Coudert B, Favier L, Lagrange A, et al. Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer. Oncoimmunology. 2017;6:e1339856. doi: 10.1080/2162402X.2017.1339856. - DOI - PMC - PubMed
1. Garg AD, Vandenberk L, Van Woensel M, Belmans J, Schaaf M, Boon L, De Vleeschouwer S, Agostinis P Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma. Oncoimmunology. 2017;6:e1295903. doi: 10.1080/2162402X.2017.1295903. - DOI - PMC - PubMed

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

Affiliations

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

Authors

Affiliations

Abstract

References

Publication types

LinkOut - more resources

Full Text Sources